Oramed Pharmaceuticals Inc (ORMP)

7.69
0.16 2.04
NASDAQ : Health Care
Prev Close 7.85
Open 7.92
Day Low/High 7.50 / 7.92
52 Wk Low/High 4.15 / 10.74
Volume 12.42K
Avg Volume 45.80K
Exchange NASDAQ
Shares Outstanding 13.29M
Market Cap 105.43M
EPS -0.90
P/E Ratio 8.26
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe And Well Tolerated In Phase Ib Study

Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe And Well Tolerated In Phase Ib Study

Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $29.5 Million in payments from HTIT received to date

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $25.5 M in payments from HTIT received to date

Oramed Announces $6.5 Million Milestone Payment From HTIT

Oramed Announces $6.5 Million Milestone Payment From HTIT

Payment comes in wake of positive topline phase IIB results

Oramed Announces Positive Top-Line Results From Phase IIb Oral Insulin Study

Oramed Announces Positive Top-Line Results From Phase IIb Oral Insulin Study

All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT

Oramed Receives Patent Term Adjustment Extending The Term Of Its U.S. Patent

Oramed Receives Patent Term Adjustment Extending The Term Of Its U.S. Patent

Patent addresses platform technology for oral insulin capsule ORMD-0801

Oramed Completes Phase IIb Oral Insulin Study

Oramed Completes Phase IIb Oral Insulin Study

Top-Line Data to be Released This Quarter

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

Oramed Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China

Oramed Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China

Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share